A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation

International Journal of Pharmaceutics

Volumn 414, Issue 1-2, 2011, Pages 225-232

  Wacker, Matthias ^a   Zensi, Anja ^a   Kufleitner, Jürgen ^a   Ruff, Aaron ^a   Schütz, Jessica ^a   Stockburger, Tobias ^a   Marstaller, Thomas ^a   Vogel, Vitali ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Albumin; Analytical ultracentrifugation; Coacervation; HSA; Industrial production; Preparation

Indexed keywords

ALCOHOL; HUMAN SERUM ALBUMIN; NANOCARRIER; NANOPARTICLE;

ARTICLE; COLLOID; DRUG DELIVERY SYSTEM; FREEZE DRYING; GRAVIMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; PROCESS CONTROL; REPRODUCIBILITY; SEDIMENTATION; SOLVATION; STORAGE; TECHNIQUE; TURBIDIMETRY; ULTRACENTRIFUGATION; ZETA POTENTIAL;

DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; ETHANOL; EXCIPIENTS; FREEZE DRYING; HUMANS; MOLECULAR WEIGHT; NANOPARTICLES; PARTICLE SIZE; SERUM ALBUMIN; SOLUBILITY; SURFACE PROPERTIES;

EID: 79959756296     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.04.046     Document Type: Article

References (20)

1. M.G. Anhorn, H.C. Mahler, and K. Langer Freeze drying of human serum albumin (HSA) nanoparticles with different excipients Int. J. Pharm. 363 2008 162 169
2. M.G. Anhorn, S. Wagner, J. Kreuter, K. Langer, and H. von Briesen Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles Bioconjug. Chem. 19 2008 2321 2331
3. S. Dreis, F. Rothweiler, M. Michaelis, J. Cinatl Jr.; J. Kreuter, and K. Langer Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles Int. J. Pharm. 341 2007 207 214 (Pubitemid 47088104)
4. I.C. Henderson, and V. Bhatia Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy Expert Rev. Anticancer Ther. 7 2007 919 943 (Pubitemid 47180894)
5. M. Holzer, V. Vogel, W. Mantele, D. Schwartz, W. Haase, and K. Langer Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage Eur. J. Pharm. Biopharm. 72 2009 428 437
6. J. Kufleitner, S. Wagner, F. Worek, H. von Briesen, and J. Kreuter Adsorption of obidoxime onto human serum albumin nanoparticles: drug loading, particle size and drug release J. Microencapsul. 27 2010 506 513
7. J. Kufleitner, F. Worek, and J. Kreuter Incorporation of obidoxime into human serum albumin nanoparticles: optimisation of preparation parameters for the development of a stable formulation J. Microencapsul. 27 2010 594 601
8. K. Langer, S. Balthasar, V. Vogel, N. Dinauer, H. von Briesen, and D. Schubert Optimization of the preparation process for human serum albumin (HSA) nanoparticles Int. J. Pharm. 257 2003 169 180 (Pubitemid 36507043)
9. Low, K.; Wacker, M.; Wagner, S.; Langer, K.; von Briesen, H.; 2011. Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells. Nanomedicine.
10. K. Michaelis, M.M. Hoffmann, S. Dreis, E. Herbert, R.N. Alyautdin, M. Michaelis, J. Kreuter, and K. Langer Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain J. Pharmacol. Exp. Ther. 317 2006 1246 1253 (Pubitemid 43764130)
11. V. Schafer, H. von Briesen, R. Andreesen, A.M. Steffan, C. Royer, S. Troster, J. Kreuter, and H. Rubsamen-Waigmann Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting Pharm. Res. 9 1992 541 546
12. X. Tang, and M.J. Pikal Design of freeze-drying processes for pharmaceuticals: practical advice Pharm. Res. 21 2004 191 200 (Pubitemid 38221965)
13. C. Vauthier, and K. Bouchemal Methods for the preparation and manufacture of polymeric nanoparticles Pharm. Res. 26 2009 1025 1058
14. V. Vogel, K. Langer, S. Balthasar, P. Schuck, W. Mächtle, W. Haase, J.A. von den Broek, C. Tziatzios, and D. Schubert Characterization of serum albumin nanoparticles by sedimentation velocity analysis and electron microscopy Progr. Colloid Polym. Sci. 119 2002 31 36
15. M. Wacker, K. Chen, A. Preuss, K. Possemeyer, B. Roeder, and K. Langer Photosensitizer loaded HSA nanoparticles. I: Preparation and photophysical properties Int. J. Pharm. 393 2010 253 262
16. S. Wagner, J. Kufleitner, A. Zensi, M. Dadparvar, S. Wien, J. Bungert, T. Vogel, F. Worek, J. Kreuter, and H. von Briesen Nanoparticulate transport of oximes over an in vitro blood-brain barrier model PLoS One 5 2010 e14213
17. H. Wartlick, K. Michaelis, S. Balthasar, K. Strebhardt, J. Kreuter, and K. Langer Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells J. Drug Target. 12 2004 461 471 (Pubitemid 39562430)
18. H. Wartlick, B. Spankuch-Schmitt, K. Strebhardt, J. Kreuter, and K. Langer Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles J. Control. Release 96 2004 483 495 (Pubitemid 38553926)
19. A. Zensi, D. Begley, C. Pontikis, C. Legros, L. Mihoreanu, C. Buchel, and J. Kreuter Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain J. Drug Target. 18 2010 842 848
20. A. Zensi, D. Begley, C. Pontikis, C. Legros, L. Mihoreanu, S. Wagner, C. Buchel, H. von Briesen, and J. Kreuter Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones J. Control. Release 137 2009 78 86